Kura Oncology Stock Alpha and Beta Analysis

KURA
 Stock
  

USD 15.13  0.43  2.93%   

This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Kura Oncology. It also helps investors analyze the systematic and unsystematic risks associated with investing in Kura Oncology over a specified time horizon. Remember, high Kura Oncology's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation.
Please see Kura Oncology Backtesting, Kura Oncology Valuation, Kura Oncology Correlation, Kura Oncology Hype Analysis, Kura Oncology Volatility, Kura Oncology History and analyze Kura Oncology Performance.
  
Please note that although Kura Oncology alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., DOW index.) So in this particular case, Kura Oncology did 0.003505  worse than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of Kura Oncology stock's relative risk over its benchmark. Kura Oncology has a beta of 0.99  . Let's try to break down what Kura Oncology's beta means in this case. Kura Oncology returns are very sensitive to returns on the market. As the market goes up or down, Kura Oncology is expected to follow.
Kura Oncology Price to Book Value is projected to increase slightly based on the last few years of reporting. The past year's Price to Book Value was at 1.84. The current year Tangible Assets Book Value per Share is expected to grow to 8.19, whereas Book Value per Share is forecasted to decline to 7.63.
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.

Enterprise Value

846.4 Million

Kura Oncology Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Kura Oncology market risk premium is the additional return an investor will receive from holding Kura Oncology long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Kura Oncology. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Kura Oncology's performance over market.
α-0.0035   β0.99
90 days against DJI

Kura Oncology expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Kura Oncology's Buy-and-hold return. Our buy-and-hold chart shows how Kura Oncology performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

Kura Oncology Market Price Analysis

Market price analysis indicators help investors to evaluate how Kura Oncology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Kura Oncology shares will generate the highest return on investment. By understating and applying Kura Oncology stock market price indicators, traders can identify Kura Oncology position entry and exit signals to maximize returns.

Kura Oncology Return and Market Media

The median price of Kura Oncology for the period between Wed, Aug 31, 2022 and Tue, Nov 29, 2022 is 14.85 with a coefficient of variation of 7.66. The daily time series for the period is distributed with a sample standard deviation of 1.12, arithmetic mean of 14.6, and mean deviation of 0.91. The Stock received substential amount of media coverage during this period.
 Price Growth (%)  
       Timeline  
1
Earnings Estimates for Kura Oncology, Inc. for Fiscal Year 2...09/23/2022
2
EPS Estimate09/30/2022
3
Should You Accumulate Kura Oncology Inc in Biotechnology Ind...10/12/2022
4
Kura Oncology to Report Third Quarter 2022 Financial Results...10/27/2022
5
EPS Reported11/03/2022
6
Transcript Kura Oncology, Inc. Presents at Credit Suisse 31s...11/09/2022
7
Is Kura Oncology Stock Outpacing Its Medical Peers This Year...11/22/2022

About Kura Oncology Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Kura Oncology or other stocks. Alpha measures the amount that position in Kura Oncology has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
 2019 2020 2021 2022 (projected)
Current Ratio15.3924.4923.2625.09
Book Value per Share5.2211.517.647.63

Kura Oncology Upcoming Company Events

As portrayed in its financial statements, the presentation of Kura Oncology's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Kura Oncology's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Kura Oncology's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Kura Oncology. Please utilize our Beneish M Score to check the likelihood of Kura Oncology's management manipulating its earnings.
Upcoming Quarterly Report23rd of February 2022
Next Financial Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End23rd of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Build Portfolio with Kura Oncology

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Kura Oncology Backtesting, Kura Oncology Valuation, Kura Oncology Correlation, Kura Oncology Hype Analysis, Kura Oncology Volatility, Kura Oncology History and analyze Kura Oncology Performance. You can also try Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Complementary Tools for analysis

When running Kura Oncology price analysis, check to measure Kura Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kura Oncology is operating at the current time. Most of Kura Oncology's value examination focuses on studying past and present price action to predict the probability of Kura Oncology's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kura Oncology's price. Additionally, you may evaluate how the addition of Kura Oncology to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Kura Oncology technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Kura Oncology technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Kura Oncology trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...